ID

28155

Description

Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00612586

Lien

https://clinicaltrials.gov/show/NCT00612586

Mots-clés

Versions (1)
  1. 22/12/2017 22/12/2017 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 décembre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Colorectal Cancer NCT00612586

Anglais

Eligibility Colorectal Cancer NCT00612586

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologic diagnosis of locally advanced or metastatic crc that is not curable. the histology types to be included are adenocarcinoma, mucinous adenocarcinoma, signet ring, and undifferentiated. patients with neuroendocrine carcinomas will be excluded.
Description

Locally Advanced Colorectal Carcinoma Incurable | Colorectal cancer metastatic incurable | Adenocarcinoma | Mucinous Adenocarcinoma | Carcinoma, Signet Ring Cell | Colorectal Undifferentiated Carcinoma | Neuroendocrine Carcinoma Excluded

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009402
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [1,4]
C0175969
UMLS CUI [2,1]
C0948380
UMLS CUI [2,2]
C0175969
UMLS CUI [3]
C0001418
UMLS CUI [4]
C0007130
UMLS CUI [5]
C0206696
UMLS CUI [6]
C1707443
UMLS CUI [7,1]
C0206695
UMLS CUI [7,2]
C2828389
received 6 cycles (3 months [12 weeks]) of first-line therapy with folfox or folfiri, plus bevacizumab for metastatic crc. patients have received at least 5 cycles with bevacizumab. patients who received 6 cycles of first-line therapy with folfox or folfiri, plus bevacizumab for recurrent crc that has relapsed at least 12 months after completion of adjuvant therapy will also be included. all standard folfox ( or folfiri) regimens given on a biweekly schedule will be permitted; however, 21-day regimens will not be allowed.
Description

First line treatment Cycle Quantity | FOLFOX Regimen | FOLFIRI Regimen | Bevacizumab | Colorectal cancer metastatic | Colorectal cancer recurrent | Adjuvant therapy Completed

Type de données

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1302181
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0392943
UMLS CUI [3]
C1880658
UMLS CUI [4]
C0796392
UMLS CUI [5]
C0948380
UMLS CUI [6]
C0854750
UMLS CUI [7,1]
C0677850
UMLS CUI [7,2]
C0205197
no more than 4 weeks may pass between the end of first-line therapy (that is, day 14 of cycle 6) and randomization.
Description

First line treatment Elapsed Time Randomization

Type de données

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C2826303
UMLS CUI [1,3]
C0034656
documented evidence of tumor response of cr, pr, or sd by computed tomography (ct) scan or magnetic resonance imaging (mri). confirmation of response is not required.
Description

In complete remission CT scan | Partial response CT scan | Stable Disease CT scan | In complete remission MRI | Partial response MRI | Stable Disease MRI

Type de données

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0040405
UMLS CUI [2,1]
C1521726
UMLS CUI [2,2]
C0040405
UMLS CUI [3,1]
C0677946
UMLS CUI [3,2]
C0040405
UMLS CUI [4,1]
C0677874
UMLS CUI [4,2]
C0024485
UMLS CUI [5,1]
C1521726
UMLS CUI [5,2]
C0024485
UMLS CUI [6,1]
C0677946
UMLS CUI [6,2]
C0024485
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
are unable to swallow tablets.
Description

Lacking Able to swallow Tablets

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C2712086
UMLS CUI [1,3]
C0039225
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Description

Drugs, Non-Prescription

Type de données

boolean

Alias
UMLS CUI [1]
C0013231
have known central nervous system metastases.
Description

CNS metastases

Type de données

boolean

Alias
UMLS CUI [1]
C0686377
are receiving concurrent administration of any other antitumor therapy.
Description

Cancer treatment

Type de données

boolean

Alias
UMLS CUI [1]
C0920425
patients who have significant heart, liver, kidney, or psychiatric disease or have an active infection
Description

Heart Disease | Liver disease | Kidney Disease | Mental disorders | Communicable Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0022658
UMLS CUI [4]
C0004936
UMLS CUI [5]
C0009450
Retour au début de la page

Similar models

Eligibility Colorectal Cancer NCT00612586

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Locally Advanced Colorectal Carcinoma Incurable | Colorectal cancer metastatic incurable | Adenocarcinoma | Mucinous Adenocarcinoma | Carcinoma, Signet Ring Cell | Colorectal Undifferentiated Carcinoma | Neuroendocrine Carcinoma Excluded
Item
histologic diagnosis of locally advanced or metastatic crc that is not curable. the histology types to be included are adenocarcinoma, mucinous adenocarcinoma, signet ring, and undifferentiated. patients with neuroendocrine carcinomas will be excluded.
boolean
C0009402 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0175969 (UMLS CUI [1,4])
C0948380 (UMLS CUI [2,1])
C0175969 (UMLS CUI [2,2])
C0001418 (UMLS CUI [3])
C0007130 (UMLS CUI [4])
C0206696 (UMLS CUI [5])
C1707443 (UMLS CUI [6])
C0206695 (UMLS CUI [7,1])
C2828389 (UMLS CUI [7,2])
First line treatment Cycle Quantity | FOLFOX Regimen | FOLFIRI Regimen | Bevacizumab | Colorectal cancer metastatic | Colorectal cancer recurrent | Adjuvant therapy Completed
Item
received 6 cycles (3 months [12 weeks]) of first-line therapy with folfox or folfiri, plus bevacizumab for metastatic crc. patients have received at least 5 cycles with bevacizumab. patients who received 6 cycles of first-line therapy with folfox or folfiri, plus bevacizumab for recurrent crc that has relapsed at least 12 months after completion of adjuvant therapy will also be included. all standard folfox ( or folfiri) regimens given on a biweekly schedule will be permitted; however, 21-day regimens will not be allowed.
boolean
C1708063 (UMLS CUI [1,1])
C1302181 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0392943 (UMLS CUI [2])
C1880658 (UMLS CUI [3])
C0796392 (UMLS CUI [4])
C0948380 (UMLS CUI [5])
C0854750 (UMLS CUI [6])
C0677850 (UMLS CUI [7,1])
C0205197 (UMLS CUI [7,2])
First line treatment Elapsed Time Randomization
Item
no more than 4 weeks may pass between the end of first-line therapy (that is, day 14 of cycle 6) and randomization.
boolean
C1708063 (UMLS CUI [1,1])
C2826303 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,3])
In complete remission CT scan | Partial response CT scan | Stable Disease CT scan | In complete remission MRI | Partial response MRI | Stable Disease MRI
Item
documented evidence of tumor response of cr, pr, or sd by computed tomography (ct) scan or magnetic resonance imaging (mri). confirmation of response is not required.
boolean
C0677874 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1521726 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3,1])
C0040405 (UMLS CUI [3,2])
C0677874 (UMLS CUI [4,1])
C0024485 (UMLS CUI [4,2])
C1521726 (UMLS CUI [5,1])
C0024485 (UMLS CUI [5,2])
C0677946 (UMLS CUI [6,1])
C0024485 (UMLS CUI [6,2])
Item Group
C0680251 (UMLS CUI)
Lacking Able to swallow Tablets
Item
are unable to swallow tablets.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
CNS metastases
Item
have known central nervous system metastases.
boolean
C0686377 (UMLS CUI [1])
Cancer treatment
Item
are receiving concurrent administration of any other antitumor therapy.
boolean
C0920425 (UMLS CUI [1])
Heart Disease | Liver disease | Kidney Disease | Mental disorders | Communicable Disease
Item
patients who have significant heart, liver, kidney, or psychiatric disease or have an active infection
boolean
C0018799 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0004936 (UMLS CUI [4])
C0009450 (UMLS CUI [5])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial